Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Quince Therapeutics, Inc. |
|---|---|
| Ticker | QNCX |
| CIK | 0001662774 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 6,8 Mio. USD |
| Beta | 1,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -83,979,000 | -1.68 | 93,523,000 | -35,714,000 | |
| 2025-09-30 | 10-Q | -13,442,000 | -0.25 | 109,899,000 | 1,059,000 | |
| 2025-06-30 | 10-Q | -16,049,000 | -0.34 | 117,210,000 | 11,736,000 | |
| 2025-03-31 | 10-Q | -15,030,000 | -0.34 | 107,089,000 | 18,581,000 | |
| 2024-12-31 | 10-K | -56,828,000 | -1.31 | 114,478,000 | 30,146,000 | |
| 2024-09-30 | 10-Q | -5,492,000 | -0.13 | 126,519,000 | 44,932,000 | |
| 2024-06-30 | 10-Q | -27,729,000 | -0.64 | 134,829,000 | 46,968,000 | |
| 2024-03-31 | 10-Q | -11,149,000 | -0.26 | 159,292,000 | 74,177,000 | |
| 2023-12-31 | 10-K | -31,385,000 | -0.84 | 167,900,000 | 85,084,000 | |
| 2023-09-30 | 10-Q | -5,351,000 | -0.15 | 85,386,000 | 83,133,000 | |
| 2023-06-30 | 10-Q | -4,886,000 | -0.14 | 88,836,000 | 86,884,000 | |
| 2023-03-31 | 10-Q | -12,254,000 | -0.34 | 93,318,000 | 90,203,000 | |
| 2022-12-31 | 10-K | -51,660,000 | -1.54 | 103,910,000 | 100,593,000 | |
| 2022-09-30 | 10-Q | -7,921,000 | -0.22 | 109,777,000 | 104,531,000 | |
| 2022-06-30 | 10-Q | -16,564,000 | -0.51 | 117,863,000 | 111,532,000 | |
| 2022-03-31 | 10-Q | -21,641,000 | -0.72 | 116,130,000 | 106,380,000 | |
| 2021-12-31 | 10-K | -89,945,000 | -3.03 | 133,228,000 | 118,586,000 | |
| 2021-09-30 | 10-Q | -21,706,000 | -0.73 | 147,416,000 | 132,652,000 | |
| 2021-06-30 | 10-Q | -21,754,000 | -0.74 | 161,390,000 | 142,080,000 | |
| 2021-03-31 | 10-Q | -23,086,000 | 174,522,000 | 156,484,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-26 | Benatti Luca | Director | Open Market Sale | -50,000 | 3.47 | -173,500.00 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.